Global pulmonary drug delivery market report published by Accurize Market Research forecast that the global market is expected to reach $52.9 billion by 2025; growing at a CAGR of 6.6% from 2017 to 2025. By geography, the Asia Pacific and North America are expected to grow at a CAGR of XX% and XX%, respectively, during the forecast period.

Request Sample: https://www.accurizemarketresearch.com/report/pulmonary-drug-delivery-systems-market/sample-request

Technological developments in the field of drug delivery and growing demand for new products, changing lifestyle, ease of use and improved facilities across the globe to drive the growth of the market

Technological developments in the field of drug delivery and growing demand for new products, changing lifestyle, ease of use and improved facilities fuels the demand for the global pulmonary drug delivery market. Moreover, the upsurge in the number of public and private organizations also boosts the growth of the market.

Market Segmentation

The global pulmonary drug delivery market has been bifurcated on the basis of product, application, and geography. On the basis of the product, it is divided into metered-dose inhalers (breath-actuated pressurized inhaler and manually-actuated pressurized inhaler), nebulizers (jet nebulizers, ultrasonic nebulizers, and vibrating mesh nebulizers), and dry powder inhalers (single dose inhalers and multi-dose inhalers). On the basis of the distributor segment, it is bifurcated into Retail Pharmacies, Hospital Pharmacies, and E-commerce. On the basis of application, the market is segmented into asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD), and others.

Request Customization: https://www.accurizemarketresearch.com/report/pulmonary-drug-delivery-systems-market/ask-for-customization

By geography, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World (RoW). The U.S., Canada, and Mexico are covered under North America wherein Europe covers the UK, Germany, France, Italy, and others. Asia-Pacific covers China, India, Japan, South Korea, and others. The rest of the World covers South America, the Middle East, and Africa.

“North America dominated the pulmonary drug delivery devices market during the forecast period”, says accurize

In 2017, North America dominated the pulmonary drug delivery devices market and Asia accounted for the second-largest regional market. Moreover, the Asia-Pacific is expected to register the highest CAGR during the forecast period due to the rapid growth of the geriatric population, growing acceptance of an unhealthy lifestyle, growing urbanization, exposure to smoke & chemicals and the successive increase in the prevalence of COPD in the area.

Top players in the market

The key market players include GlaxoSmithKline plc, Novartis AG, Koninklijke Philips N.V., 3M Company, Actelion Pharmaceuticals Ltd, AstraZeneca plc, BoehringerIngelheimGmbh, Clement Clarke International, Briggs Healthcare, and Aerogenamong others.